- Efficacy
- Prof. Carvalho Treat Early & Effectively
- Prof. Davies Wealth of Evidence in Early HbA1c control
- Prof. Cooper Early Glycemic Control in T2D
- A single powerful combination pill
- Early glycemic control in treating T2D patients
- Recorded webinar of Mark Cooper last July 1, 2020
- Professor Javier Ampudia Webinar “Expanding Treatment Options for Glycemic Reduction in Patients with T2DM: Role of Empagliflozin+Linagliptin Combination
- Multiple Benefits in one small pill
- 2020 American Association of Clinical Endocrinology Guidelines
- Advantage of Glyxambi over other FDC
- Efficacy
- Recorded webinar of Ralph De Fronzo
- Glyxambi Microsite Demo Video
- Overcoming challenges in glycemic control
- MPPGLY||Glyxambi is beneficial in T2D patients with no Established CV Disease
- MPPGLY||Consistent renal benefit of individual components
- Safety
- External Expert video on Early Intensive Treatment
- External Expert video on Glyxambi's unique advantages
- Cardiovascular & Renal Safety
- Prof. Ralph De Fronzo’s expert opinion on the safety profile of Glyxambi
- Prof. Ralph De Fronzo’s expert opinion why Glyxambi is a good combination in T2D
- Be in control across CRM Outcomes in T2D
- Non adherence: Not just WHEN but WHY
- Non-adherence in medication among T2D Patients
- Mode of Action
- Prescribing Information
- CV and RENAL SAFETY
